PLCG2 and thrombotic disease: Since GPVI is an encouraging pharmacological target for the active and safe treatment of thrombotic diseases [6], inhibition of PLCγ2, PKC, and adenosine triphosphate (ATP) release are the major targets for the treatment of thrombotic diseases.